The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.
White Paper
IND Ready Is Not Phase 2 Ready
Related Resources
All Resources
case-study
Partnership helped to reduce time to market by ensuring for U.S. based virtual Biopharmaceutical company
Read More
case-study
Process improvements and in-person monitoring help U.S. pharmaceutical company achieve on time for Phase III clinical trials
Read More
post
Exploring Risk-Based Approaches to Raw Material Testing in Pharmaceutical Manufacturing
Read More
post
Potency Assurance for Cellular and Gene Therapy Products
Read More
Let's move from science to success.
Let’s Talk